Our study complements these in vitro findings by demonstrating that heterozygous Rnpc3 expression is sufficient to reduce tumour burden in a variety of in vivo cancer models from zebrafish and mice, including those driven by mutant Kras oncogenes. Here, KRAS is linked to cancer.